OmniAb (OABI) Gross Margin (2024 - 2026)
OmniAb (OABI) reported Gross Margin of 99.9% for Q1 2026, down 3.0% year-over-year from 102.99% in Q1 2025, and little changed quarter-over-quarter from 99.89% in Q4 2025.
OmniAb (OABI) Gross Margin (2024 - 2026) Analysis & Trends
OmniAb (OABI) has 3 years of Gross Margin data on file, last reported at 99.9% in Q1 2026.
- Gross Margin for Q1 2026 came in at 99.9%, down 3.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 98.91% (down 108.0% YoY), and the FY2025 annual result was 98.38%, down 162.0% from the prior year.
- Gross Margin was little changed at 99.9% in Q1 2026 per OABI's latest filing, from 99.89% in the prior quarter.
- Over five years, Gross Margin peaked at 100.0% in Q2 2024 and troughed at 93.28% in Q2 2025.
- A 3-year average of 98.96% and a median of 99.91% in 2025 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2025 and 2026: Gross Margin plunged 672 bps in 2025, then declined 3 bps in 2026.
- A 3-year view of Gross Margin shows it stood at 100.0% in 2024, then fell by 0 bps to 99.89% in 2025, then increased by 0 bps to 99.9% in 2026.
- Business Quant data shows OABI's Gross Margin at 99.9% in Q1 2026, 99.89% in Q4 2025, and 98.7% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 79.04% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 86.85% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 99.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 99.90% |
| Dec 31, 2025 | 99.89% |
| Sep 30, 2025 | 98.70% |
| Jun 30, 2025 | 93.28% |
| Mar 31, 2025 | 99.93% |
| Dec 31, 2024 | 100.00% |
| Sep 30, 2024 | 100.00% |
| Jun 30, 2024 | 100.00% |